| Literature DB >> 35525841 |
Yura Ahn1, Se Jin Choi1, Soyeoun Lim2, Joon Bum Kim3, Jong-Min Song4, Duk-Hyun Kang4, Jae-Kwan Song4, Hwa Jung Kim5, Joon-Won Kang1, Dong Hyun Yang1, Dae-Hee Kim6, Hyun Jung Koo7.
Abstract
Aortic valve calcium scoring by cardiac computed tomographic (CT) has been recommended as an alternative to classify the AS (aortic stenosis) severity, but it is unclear that whether CT findings would have additional value to discriminate significant AS subtypes including high gradient severe AS, classic low-flow, low gradient (LF-LG) AS, paradoxical LF-LG AS, and moderate AS. In this study, we examined the preoperative clinical and cardiac CT findings of different subtypes of AS in patients with surgical aortic valve replacement (AVR) and evaluated the subtype classification as a factor affecting post-surgical outcomes. This study included 511 (66.9 ± 8.8 years, 55% men) consecutive patients with severe AS who underwent surgical AVR. Aortic valve area (AVA) was obtained by echocardiography (AVAecho) and by CT (AVACT) using each modalities measurement of the left ventricular outflow tract. Patients with AS were classified as (1) high-gradient severe (n = 438), (2) classic LF-LG (n = 18), and (3) paradoxical LF-LG (n = 55) based on echocardiography. In all patients, 455 (89.0%) patients were categorized as severe AS according to the AVACT. However, 56 patients were re-classified as moderate AS (43 [9.8%] high-gradient severe AS, 5 [27.8%] classic LF-LG AS, and 8 [14.5%] paradoxical LF-LG AS) by AVACT. The classic LF-LG AS group presented larger AVACT and aortic annulus than those in high-gradient severe AS group and one third of them had AVACT ≥ 1.2 cm2. After multivariable adjustment, old age (hazard ratio [HR], 1.04, P = 0.049), high B-type natriuretic peptide (BNP) (HR, 1.005; P < 0.001), preoperative atrial fibrillation (HR, 2.75; P = 0.003), classic LF-LG AS (HR, 5.53, P = 0.004), and small aortic annulus on CT (HR, 0.57; P = 0.002) were independently associated with major adverse cardiac and cerebrovascular events (MACCE) after surgical AVR.Entities:
Mesh:
Year: 2022 PMID: 35525841 PMCID: PMC9079063 DOI: 10.1038/s41598-022-11491-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Clinical and imaging characteristics of high-gradient severe, classic LF-LG, paradoxical LF-LG AS groups (n = 511).
| Characteristic | High-gradient severe AS | Classic LF-LG AS | Paradoxical LF-LG AS | P-value |
|---|---|---|---|---|
| No. of patients (%) | 438 (85.7) | 18 (3.5) | 55 (10.8) | |
| Age, years | 66.8 ± 8.8 | 66.8 ± 6.2 | 67.3 ± 9.4 | 0.93 |
| Male | 236 (53.9) | 13 (72.2) | 31 (56.4) | 0.30 |
| BSA, m2 | 1.6 ± 0.2 | 1.7 ± 0.2 | 1.6 ± 0.2 | 0.56 |
| Hypertension | 231 (52.7) | 12 (66.7) | 30 (54.5) | 0.50 |
| Atrial fibrillation | 65 (14.8) | 4 (22.2) | 4 (7.3) | 0.20 |
| PCI or CABG | 94 (21.5) | 9 (50.0)* | 14 (25.5) | 0.02 |
| BNP, pg/mL | 99.5 (43.0–280.5) | 944.5 (304.8–3066.0)* | 70.0 (35.0–190.0) | < 0.001 |
| lnBNP | 4.6 (3.8–5.6) | 6.8 (5.7–8.0)* | 4.2 (3.6–5.2) | < 0.001 |
| LVEF, % | 60.3 ± 10.0 | 36.0 ± 10.3* | 62.6 ± 5.3 | < 0.001 |
| Peak velocity, m/s | 5.2 ± 0.7 | 3.6 ± 0.5* | 3.5 ± 0.5† | < 0.001 |
| Peak PG, mmHg | 108.5 ± 30.5 | 52.0 ± 13.1* | 50.1 ± 16.0† | < 0.001 |
| Mean PG, mmHg | 66.5 ± 19.4 | 29.8 ± 7.9* | 28.0 ± 9.5† | < 0.001 |
| LVMI, g/m2 | 135.4 ± 35.8 | 149.6 ± 31.1 | 124.9 ± 36.2 | 0.03 |
| AV VTI, cm | 124.6 ± 26.1 | 94.9 ± 33.3* | 112.0 ± 27.7† | < 0.001 |
| LVOT VTI, cm | 21.4 ± 4.1 | 16.0 ± 4.4* | 21.2 ± 3.7 | < 0.001 |
| LVOT diameter, mm | 21.0 ± 1.5 | 21.8 ± 1.9 | 21.2 ± 1.6 | 0.06 |
| LVOT diameter/BSA | 12.9 ± 1.3 | 13.1 ± 1.6 | 13.0 ± 1.3 | 0.55 |
| AVAecho, mm2 | 61.3 ± 14.7 | 66.9 ± 15.1 | 69.5 ± 13.8† | < 0.001 |
| ESVI, mL/m2 | 27.7 ± 16.8 | 63.4 ± 27.0* | 24.5 ± 11.4 | < 0.001 |
| EDVI, mL/m2 | 66.8 ± 23.7 | 96.3 ± 29.3* | 64.3 ± 24.5 | < 0.001 |
| SAC, mL/m2/mmHg | 0.8 ± 0.3 | 0.7 ± 0.3 | 0.8 ± 0.3 | 0.28 |
| Zva, mmHg/mL/m2 | 5.3 ± 1.6 | 5.0 ± 1.9 | 4.4 ± 1.4† | < 0.001 |
| Valve morphology | 0.04 | |||
| Tricuspid | 204 (46.6) | 14 (77.8) | 28 (50.9) | |
| Bicuspid with raphe | 106 (24.2) | 3 (16.7) | 17 (30.9) | |
| Bicuspid without raphe | 128 (29.2) | 1 (5.6) | 10 (18.2) | |
| AVC, Agatston unit | 3027.2 ± 1872.0 | 2895.5 ± 1624.5 | 2363.1 ± 1605.8† | 0.04 |
| AVCratio‡ | 1.8 ± 1.0 | 1.6 ± 0.8 | 1.4 ± 0.8† | 0.006 |
| LVOT mean diameter | 24.8 ± 2.9 | 27.1 ± 2.7* | 24.7 ± 2.6 | 0.003 |
| AVACT, mm2 | 84.9 ± 23.4 | 100.8 ± 22.7* | 94.2 ± 25.0† | 0.001 |
| AVAplani, mm2 | 87.2 ± 23.2 | 99.7 ± 25.5* | 97.5 ± 27.1† | 0.003 |
| Aortic annulus | ||||
| Circularity, % | 81.6 ± 7.6 | 77.4 ± 6.6 | 82.3 ± 6.0 | 0.05 |
| Maximal dimeter, mm | 27.5 ± 3.2 | 30.4 ± 3.5* | 27.4 ± 2.8 | 0.001 |
| Mean diameter, mm | 24.9 ± 2.6 | 26.9 ± 2.5* | 25.0 ± 2.6 | 0.005 |
| Perimeter, mm | 79.5 ± 8.4 | 85.4 ± 7.7* | 80.0 ± 8.3 | 0.02 |
| Area, mm2 | 481.8 ± 102.4 | 554.8 ± 101.0* | 489.5 ± 99.9 | 0.01 |
| Sinus of Valsalva, mm | 36.6 ± 4.5 | 38.4 ± 4.7 | 36.8 ± 5.0 | 0.25 |
| Sinotubular junction, mm | 30.9 ± 4.6 | 31.7 ± 3.3 | 31.5 ± 5.9 | 0.58 |
| Ascending aorta tubular portion, mm | 40.7 ± 6.3 | 38.4 ± 4.6 | 40.4 ± 7.7 | 0.31 |
| AVACT, mm2 | 51.7 ± 13.6 | 60.7 ± 15.8* | 58.0 ± 15.6† | < 0.001 |
| AVAplani, mm2 | 52.6 ± 13.5 | 59.5 ± 17.5* | 57.8 ± 15.2† | 0.005 |
| Aortic annulus | ||||
| Maximal dimeter, mm | 16.8 ± 2.0 | 18.2 ± 2.6* | 16.9 ± 1.7 | 0.01 |
| Mean diameter, mm | 15.2 ± 1.6 | 16.1 ± 1.9 | 15.4 ± 1.6 | 0.06 |
| Perimeter, mm | 48.7 ± 5.2 | 51.1 ± 5.8 | 49.2 ± 5.3 | 0.12 |
| Area, mm2 | 293.4 ± 55.5 | 331.0 ± 56.6* | 299.7 ± 55.9 | 0.02 |
| Sinus of Valsalva, mm | 22.4 ± 2.9 | 23.0 ± 2.8 | 22.6 ± 2.9 | 0.65 |
| Sinotubular junction diameter, mm | 18.9 ± 2.9 | 18.9 ± 2.1 | 19.3 ± 3.2 | 0.69 |
| Ascending aorta tubular portion, mm | 25.0 ± 4.3 | 23.0 ± 2.9 | 24.8 ± 4.6 | 0.15 |
| Surgical valve size, mm | 22.1 ± 2.1 | 23.0 ± 2.1 | 22.3 ± 2.0 | 0.18 |
| N/A | ||||
| CE Magna | 144 | 10 | 18 | |
| ATSAP | 82 | 4 | 8 | |
| Hancock | 82 | 1 | 13 | |
| St. Jude Regent | 80 | 3 | 11 | |
| Others | 50 | 0 | 5 | |
| 0.47 | ||||
| Operator 1 | 170 | 5 | 18 | |
| Operator 2 | 95 | 2 | 12 | |
| Operator 3 | 81 | 4 | 15 | |
| Operator 4 | 64 | 4 | 7 | |
| Operator 5 | 28 | 3 | 3 | |
| MACCE | 34 (7.8) | 5 (27.8)* | 4 (7.3) | 0.01 |
| All-cause mortality | 57 (13.0) | 6 (33.3) | 8 (14.5) | 0.05 |
| Follow-up duration, d | 1517.5 (1188.8–2026.5) | 1134.0 (26.0–1682.0) | 1455.0 (1112.0–1944.0) | 0.007 |
Values are means ± standard deviations or numbers and percentages in parentheses.
*Significant difference between patients with high-gradient severe aortic stenosis and patients with classic LF-LG AS groups.
†Significant difference between high-gradient severe aortic stenosis and paradoxical LF-LG AS groups.
‡Value divided by sex-specific thresholds (Male, 2000; Female, 1250).
AS aortic stenosis, AV aortic valve, AVA aortic valve area, AVC aortic valve calcium score, BNP B-type natriuretic peptide, CABG coronary artery bypass graft, EDVI end-diastolic volume index, ESVI end-systolic volume index, LF-LG low-flow and low-gradient, lnBNP log-transformed B-type natriuretic peptide, LVEF left ventricular ejection fraction, LVMI left ventricular mass index, LVOT left ventricular outflow tract, MACCE major adverse cardiac and cerebrovascular event, N/A not available, PCI percutaneous coronary artery intervention, PG pressure gradient, SAC systemic arterial compliance, VTI velocity time integral, Zva valvulo-arterial impedance.
Figure 1Box plot to demonstrate the distribution of AVAecho, AVACT, and AVAplani according to categories of AS. AS aortic stenosis, AVA aortic valve area, LF-LG low-flow and low-gradient.
Subgroups of LF-LG AS according to AVACT.
| Characteristic | High-gradient severe AS (n = 438) | Classic LF-LG AS (n = 18) | Paradoxical LF-LG AS (n = 55) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| AVACT < 1.2 cm2 | AVACT ≥ 1.2 cm2 | P-value | AVACT < 1.2 cm2 | AVACT ≥ 1.2 cm2 | P-value | AVACT < 1.2 cm2 | AVACT ≥ 1.2 cm2 | P-value | |
| No. of patients (%) | 395 (90.2) | 43 (9.8) | 13 (72.2) | 5 (27.8) | 47 (85.5) | 8 (14.5) | |||
| Age, years | 66.8 ± 8.9 | 67.0 ± 8.4 | 0.92 | 66.1 ± 5.8 | 68.6 ± 7.7 | 0.46 | 67.3 ± 9.2 | 67.3 ± 10.9 | 0.99 |
| Male | 201 (50.9) | 35 (81.4) | < 0.001 | 9 (69.2) | 4 (80.0) | 1.00 | 25 (53.2) | 6 (75.0) | 0.72 |
| BSA, m2 | 1.6 ± 0.2 | 1.7 ± 0.2 | < 0.001 | 1.7 ± 0.2 | 1.6 ± 0.2 | 0.12 | 1.6 ± 0.2 | 1.7 ± 0.1 | 0.34 |
| Hypertension | 208 (52.7) | 23 (53.5) | 1.00 | 7 (53.8) | 5 (100.0) | 0.11 | 26 (55.3) | 4 (50.0) | 1.00 |
| Atrial fibrillation | 59 (14.9) | 6 (14.0) | 1.00 | 3 (23.1) | 1 (20.0) | 1.00 | 2 (4.3) | 2 (25.0) | 0.10 |
| PCI or CABG | 88 (22.3) | 6 (14.0) | 0.29 | 6 (46.2) | 3 (60.0) | 1.00 | 14 (25.5) | 0 (0.0) | 0.10 |
| Rheumatic valvular disease | 37 (9.4) | 1 (2.3) | 0.12 | 2 (15.4) | 0 (0.0) | 1.00 | 6 (12.8) | 2 (25.0) | 0.33 |
| B-type natriuretic peptide, pg/mL | 106.0 (49.0 –282.5) | 51.0 (31.0 –190.5) | 0.05 | 1118.0 (304.8–3066.0) | 738.5 (239.3–3227.5) | 0.80 | 59.0 (32.5–180.5) | 200.5 (59.0–305.3) | 0.38 |
| lnBNP | 4.7 (3.9–5.6) | 3.9 (3.4–5.2) | 0.05 | 7.0 (5.7–8.0) | 6.6 (5.0–7.9) | 0.60 | 4.1 (3.5–5.2) | 5.2 (4.1–5.7) | 0.12 |
| Blood urea nitrogen, mg/dL | 17.7 ± 7.2 | 20.4 ± 10.2 | 0.10 | 25.2 ± 16.7 | 18.6 ± 4.7 | 0.22 | 18.8 ± 8.5 | 18.0 ± 4.7 | 0.81 |
| Creatinine, mg/dL | 0.9 ± 0.6 | 1.4 ± 1.9 | 0.09 | 2.1 ± 2.3 | 1.9 ± 1.3 | 0.76 | 1.0 ± 0.4 | 0.9 ± 0.1 | 0.46 |
| LVEF, % | 60.3 ± 10.1 | 60.8 ± 8.9 | 0.72 | 36.9 ± 11.2 | 33.8 ± 8.0 | 0.59 | 62.8 ± 5.4 | 61.5 ± 4.6 | 0.53 |
| Peak velocity, m/s | 5.2 ± 0.7 | 4.9 ± 0.6 | 0.006 | 3.6 ± 0.4 | 3.4 ± 0.7 | 0.37 | 3.5 ± 0.5 | 3.6 ± 0.6 | 0.67 |
| Peak PG, mmHg | 109.8 ± 31.0 | 96.9 ± 22.4 | 0.001 | 53.5 ± 11.7 | 48.0 ± 17.0 | 0.44 | 49.5 ± 16.0 | 53.4 ± 16.9 | 0.53 |
| Mean PG, mmHg | 67.3 ± 19.7 | 58.5 ± 14.7 | 0.001 | 30.8 ± 6.8 | 27.2 ± 10.6 | 0.41 | 27.7 ± 9.4 | 29.8 ± 10.2 | 0.59 |
| LVMI, g/m2 | 135.4 ± 35.8 | 134.8 ± 36.5 | 0.91 | 151.5 ± 33.5 | 144.7 ± 26.3 | 0.69 | 121.5 ± 32.7 | 144.6 ± 50.6 | 0.10 |
| AV VTI, cm | 127.2 ± 25.7 | 101.0 ± 16.5 | < 0.001 | 101.3 ± 34.2 | 78.2 ± 26.9 | 0.20 | 114.2 ± 28.2 | 98.9 ± 21.3 | 0.15 |
| LVOT VTI, cm | 21.3 ± 4.1 | 22.6 ± 3.6 | 0.04 | 16.0 ± 4.8 | 16.2 ± 3.8 | 0.92 | 21.4 ± 3.6 | 19.7 ± 3.7 | 0.24 |
| LVOT diameter, mm | 21.0 ± 1.5 | 21.4 ± 1.5 | 0.10 | 22.1 ± 2.2 | 21.2 ± 0.2 | 0.22 | 21.0 ± 1.4 | 22.2 ± 2.2 | 0.18 |
| LVOT diameter/BSA | 12.9 ± 1.3 | 12.3 ± 1.0 | < 0.001 | 12.9 ± 1.6 | 13.6 ± 1.4 | 0.40 | 13.0 ± 1.4 | 13.2 ± 1.2 | 0.75 |
| AVAecho, mm2 | 59.0 ± 13.6 | 80.4 ± 8.8 | < 0.001 | 61.1 ± 12.8 | 81.9 ± 9.1 | 0.005 | 68.2 ± 13.6 | 77.3 ± 12.7 | 0.08 |
| ESVI | 27.7 ± 16.9 | 28.0 ± 16.4 | 0.92 | 63.0 ± 30.0 | 64.4 ± 20.0 | 0.92 | 23.4 ± 10.6 | 30.7 ± 14.5 | 0.10 |
| EDVI | 66.6 ± 23.4 | 68.7 ± 26.7 | 0.57 | 96.4 ± 32.6 | 95.9 ± 21.3 | 0.98 | 62.0 ± 22.6 | 78.4 ± 31.5 | 0.08 |
| SAC, mL/m2/mmHg | 0.8 ± 0.3 | 0.8 ± 0.3 | 0.11 | 0.7 ± 0.3 | 0.6 ± 0.1 | 0.52 | 0.7 ± 0.3 | 1.0 ± 0.5 | 0.21 |
| Zva, mmHg/mL/m2 | 5.4 ± 1.6 | 5.2 ± 1.7 | 0.51 | 4.7 ± 1.7 | 5.8 ± 2.2 | 0.82 | 4.5 ± 1.4 | 3.8 ± 1.5 | 0.21 |
| Valve morphology | 0.04 | 0.28 | 0.14 | ||||||
| Tricuspid | 177 (44.8) | 27 (62.8) | 9 (69.2) | 5 (100.0) | 26 (55.3) | 2 (25.0) | |||
| Bicuspid | 218 (55.2) | 16 (37.2) | 4 (30.8) | 0 (0.0) | 21 (44.7) | 6 (75.0) | |||
| AVC, Agatston unit | 2834.2 (1605.2–4178.4) | 2426.7 (1616.1–3808.9) | 0.57 | 3912.2 (2247.0–4496.1) | 1360.1 (960.1–2108.6) | 0.002 | 2002.4 (1192.2–2841.6) | 2584.3 (1306.5–5172.0) | 0.12 |
| AVACT | 80.9 ± 18.8 | 136.6 ± 29.6 | < 0.001 | 92.4 ± 15.5 | 122.7 ± 25.2 | 0.007 | 90.2 ± 22.4 | 117.7 ± 27.9 | 0.003 |
| AVAplani, mm2 | 85.2 ± 22.1 | 105.0 ± 26.1 | < 0.001 | 88.2 ± 20.0 | 129.9 ± 5.4 | < 0.001 | 90.1 ± 21.2 | 140.9 ± 13.8 | < 0.001 |
| LVOT area | 346.8 ± 50.0 | 359.6 ± 51.3 | 0.11 | 587.5 ± 129.7 | 572.3 ± 79.9 | 0.81 | 468.9 ± 94.5 | 581.3 ± 94.9 | 0.003 |
| Aortic annulus | |||||||||
| Maximum diameter, mm | 27.1 ± 3.0 | 30.6 ± 3.2 | < 0.001 | 30.6 ± 3.9 | 30.0 ± 2.1 | 0.77 | 27.1 ± 2.6 | 29.0 ± 3.6 | 0.05 |
| Circularity, % | 80.0 ± 1.0 | 80.0 ± 1.0 | 0.22 | 77.6 ± 7.5 | 76.9 ± 4.4 | 0.84 | 82.0 ± 5.7 | 83.8 ± 7.6 | 0.18 |
| Mean diameter, mm | 24.6 ± 2.5 | 27.5 ± 2.6 | < 0.001 | 27.1 ± 2.9 | 26.5 ± 1.4 | 0.70 | 24.7 ± 2.3 | 27.0 ± 3.0 | 0.01 |
| Perimeter, mm | 78.7 ± 8.0 | 87.3 ± 8.6 | < 0.001 | 86.0 ± 8.9 | 83.8 ± 3.7 | 0.46 | 78.7 ± 7.4 | 87.3 ± 10.0 | 0.01 |
| Area, mm2 | 471.4 ± 95.0 | 576.8 ± 119.4 | < 0.001 | 563.3 ± 116.1 | 532.8 ± 45.9 | 0.44 | 475.2 ± 91.3 | 572.9 ± 113.2 | 0.009 |
| Sinus of Valsalva, mm | 36.2 ± 4.5 | 39.4 ± 3.8 | < 0.001 | 39.3 ± 4.9 | 36.1 ± 3.4 | 0.20 | 35.9 ± 4.6 | 42.0 ± 4.2 | 0.001 |
| Sinotubular junction, mm | 30.7 ± 4.6 | 32.8 ± 4.4 | 0.004 | 32.1 ± 3.5 | 30.7 ± 2.8 | 0.44 | 30.6 ± 5.1 | 36.7 ± 7.7 | 0.006 |
| Ascending aorta, mm | 40.7 ± 6.3 | 41.0 ± 5.8 | 0.74 | 39.5 ± 4.4 | 35.5 ± 4.2 | 0.10 | 39.6 ± 7.1 | 45.1 ± 9.8 | 0.06 |
| AVACT | 51.8 ± 13.0 | 59.7 ± 15.7 | < 0.001 | 53.9 ± 9.4 | 78.3 ± 16.1 | 0.001 | 55.9 ± 14.3 | 70.3 ± 17.9 | 0.01 |
| AVAplani, mm2 | 52.4 ± 13.5 | 60.9 ± 16.4 | < 0.001 | 51.5 ± 12.3 | 82.7 ± 6.0 | < 0.001 | 55.7 ± 12.7 | 84.1 ± 10.4 | < 0.001 |
| LVOT area, mm2 | 294.1 ± 61.4 | 322.3 ± 62.4 | 0.005 | 341.2 ± 69.4 | 365.5 ± 54.6 | 0.50 | 289.3 ± 55.3 | 345.5 ± 54.4 | 0.01 |
| Aortic annulus | |||||||||
| Maximal dimeter, mm | 16.7 ± 1.9 | 17.7 ± 2.0 | 0.002 | 17.9 ± 2.8 | 19.2 ± 2.0 | 0.35 | 16.8 ± 1.7 | 17.4 ± 1.6 | 0.37 |
| Mean diameter, mm | 15.2 ± 1.6 | 15.9 ± 1.6 | 0.006 | 15.8 ± 2.0 | 17.0 ± 1.7 | 0.27 | 15.3 ± 1.6 | 16.1 ± 1.6 | 0.20 |
| Perimeter, mm | 48.5 ± 5.2 | 50.4 ± 5.1 | 0.02 | 50.2 ± 6.0 | 53.6 ± 5.0 | 0.28 | 48.7 ± 4.9 | 52.0 ± 6.8 | 0.10 |
| Area, mm2 | 289.3 ± 53.4 | 331.3 ± 60.0 | < 0.001 | 327.6 ± 65.3 | 339.7 ± 26.4 | 0.70 | 292.7 ± 50.4 | 341.4 ± 71.4 | 0.02 |
| Sinus of Valsalva | 36.2 ± 4.5 | 39.4 ± 3.8 | < 0.001 | 22.9 ± 3.0 | 23.0 ± 2.4 | 0.95 | 22.1 ± 2.6 | 25.1 ± 3.5 | 0.007 |
| Sinotubular junction diameter | 30.7 ± 4.6 | 32.8 ± 4.4 | 0.004 | 18.7 ± 1.9 | 19.6 ± 2.5 | 0.40 | 18.9 ± 2.5 | 21.9 ± 5.3 | 0.01 |
| Ascending aorta tubular portion | 40.7 ± 6.3 | 41.0 ± 5.8 | 0.74 | 23.1 ± 3.0 | 22.6 ± 2.9 | 0.78 | 24.5 ± 4.3 | 26.9 ± 5.7 | 0.18 |
| Surgical valve size, mm | 21.9 ± 2.1 | 23.5 ± 1.8 | < 0.001 | 23.2 ± 2.3 | 22.6 ± 1.7 | 0.63 | 22.1 ± 2.1 | 23.3 ± 1.7 | 0.14 |
| MACCE (cardiovascular death) | 30 (7.6) | 4 (9.3) | 0.92 | 2 (15.4) | 3 (60.0) | 0.10 | 4 (8.5) | 0 (0.0) | 1.00 |
| All-cause mortality | 52 (13.2) | 5 (11.6) | 0.96 | 4 (30.8) | 2 (40.0) | 1.00 | 7 (14.9) | 1 (12.5) | 1.00 |
AS, aortic stenosis; AVA, aortic valve area; AVACT, AVA measured on CT; AVC, aortic valve calcium score; BSA, body surface area; CABG, coronary artery bypass graft; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; LF-LG, low-flow and low-gradient; lnBNP, log-transformed B-type natriuretic peptide; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; LVOT, left ventricular outflow tract; MACCE, major adverse cardiac and cerebrovascular event; PCI, percutaneous coronary artery intervention; VTI, velocity time integral.
Figure 2(a) Pearson correlation analysis result and (b) Bland–Altman plot to comparison of AVACT and AVAecho. AS aortic stenosis, AVA aortic valve area, LF-LG low-flow and low-gradient.
Figure 3Box plot to demonstrate the distribution of AVCratio, LVOT mean diameter, and maximal diameter of aortic annulus according to subtypes. (a) AVCratio was calculated by dividing AVC with sex-specific thresholds (Male, 2000; Female, 1250). The score above the red-dotted line represents AVC above the sex-specific threshold, and consequently, severe aortic stenosis. The score below the red-dotted line represents the AVC below the sex-specific threshold and nonsevere calcification. The mean of AVCratio was significantly lower in paradoxical LF-LG AS than that of high gradient severe AS (P = 0.001). In addition, the proportion of nonsevere calcification was most frequent in paradoxical LF-LG AS patients. Both (b) LVOT mean diameter and (c) maximal diameter of aortic annulus were lowest in LF-LG AS patients among the three subtypes and significantly larger than those of high-gradient severe AS patients. AS aortic stenosis, AVC aortic valve calcium score, LF-LG low-flow and low-gradient, LVOT left ventricular outflow tract.
Cox proportional hazard regression model for prediction of MACCE.
| Parameter | Univariate | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age, years | 1.06 (1.02–1.10) | 0.005 | 1.04 (1.00–1.09) | 0.049 |
| BSA, m2 | 0.49 (0.08–3.15) | 0.45 | ||
| B-type natriuretic peptide, 10 pg/mL | 1.01 (1.003–1.01) | < 0.001 | 1.005 (1.003–1.01) | < 0.001 |
| lnBNP | 1.42 (1.13–1.77) | 0.002 | ||
| Atrial fibrillation, (%) | 3.22 (1.70–6.11) | < 0.001 | 2.75 (1.40–5.40) | 0.003 |
| LVEF, % | 0.98 (0.96–1.01) | 0.20 | ||
| Peak velocity, m/s | 0.80 (0.57–1.12) | 0.19 | ||
| Mean PG, mmHg | 0.99 (0.98–1.01) | 0.21 | ||
| LVMI, g/m2 | 0.99 (0.99–1.00) | 0.18 | ||
| ESVI, mL/m2 | 1.01 (0.99–1.02) | 0.55 | ||
| EDVI, mL/m2 | 1.00 (0.99–1.01) | 0.90 | ||
| SAC, mL/m2/mmHg | 0.57 (0.21–1.53) | 0.27 | ||
| Zva, mmHg/mL/m2 | 1.00 (0.83–1.20) | 0.98 | ||
| Bicuspid aortic valve | 0.40 (0.21–0.77) | 0.006 | ||
| Classic LF-LG AS | 5.04 (1.98–12.84) | 0.001 | 5.53 (1.74–17.56) | 0.004 |
| AVAecho, m2 | 1.01 (0.99–1.03) | 0.60 | ||
| AV VTI, cm | 0.98 (0.96–0.99) | < 0.001 | ||
| LVOT VTI, cm | 0.92 (0.86–0.99) | 0.02 | ||
| lnAVC | 0.89 (0.71–1.09) | 0.26 | ||
| Normalized AVAplani, mm2 | 1.00 (0.98–1.03) | 0.76 | ||
| Normalized AVACT, mm2 | 1.02 (1.00–1.04) | 0.50 | ||
| Annulus circularity, % | 0.34 (0.01–18.69) | 0.59 | ||
| Aortic annulus area, cm2 | 0.73 (0.53–1.01) | 0.06 | 0.57 (0.40–0.81) | 0.002 |
| Surgical valve size, mm | 0.89 (0.77–1.04) | 0.13 | ||
| CE Magna | 1 | 0.63 | ||
| ATSAP | 0.55 (0.20–1.48) | 0.24 | ||
| Hancock | 1.09 (0.50–2.38) | 0.83 | ||
| St. Jude Regent | 0.63 (0.25–1.59) | 0.32 | ||
| Others | 0.85 (0.31–2.31) | 0.75 | ||
| Operator 1 | 1 | 0.33 | ||
| Operator 2 | 1.63 (0.78–3.38) | 0.19 | ||
| Operator 3 | 0.37 (0.05–2. 76) | 0.33 | ||
| Operator 4 | 0.94 (0.37–2.41) | 0.90 | ||
| Operator 5 | 0.73 (0.30–1.78) | 0.49 | ||
AS aortic stenosis, AVA aortic valve area, AVC aortic valve calcium score, CI confidence interval, EDVI end-diastolic volume index, ESVI end-systolic volume index, HR hazard ratio, LF-LG low-flow and low-gradient, lnBNP log-transformed B-type natriuretic peptide, LVEF left ventricular ejection fraction, LVMI left ventricular mass index, LVOT left ventricular outflow tract, MACCE major adverse cardiac and cerebrovascular event, PG pressure gradient, SAC systemic arterial compliance, VTI velocity time integral, Zva valvulo-arterial impedance.
Figure 4Survival according to (a) B-type natriuretic peptide, (b) presence of atrial fibrillation, and (c) categories of aortic stenosis. AS aortic stenosis, LF-LG low-flow and low-gradient.
Figure 5Characteristics of classic LF-LG AS. Classic LF-LG AS patients demonstrated higher ESVI and EDVI, lower LVEF, larger aortic annulus diameter and area compared to high-gradient severe AS. The drawings were prepared using Photoshop 2019 (version 20). AS aortic stenosis, BNP B-type natriuretic peptide, EDVI end-diastolic volume index, ESVI end-systolic volume index, LVEF left ventricular ejection fraction.